Liver Transplant Clinical Trial
Official title:
Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery: A Randomized Controlled Bi-Center Equivalence Trial
Intraoperative cell salvage is commonly used in surgeries that carry a major hemorrhagic risk to reduce the administration of allogeneic red blood cells and thus improve the outcome for the patient. When processing the salvaged blood, however, a large part of the patient's plasma is washed out. This is a disadvantage with regard to an optimal coagulation status after these types of surgeries, especially liver transplantation. There are currently various cell saver systems on the market. According to the manufacturers, the plasma is returned to the patient in different quantities as part of the processing procedure. Thus, it can be assumed that in addition to red blood cells, platelets (part of plasma) are re-transfused and contribute to an optimized coagulation. Unfortunately, there is a lack of studies in this regard in the liver transplant surgery population. The investigators aim to study the performance of two different cell saver devices regarding preservation of platelet number and function.
- Study design: Randomized controlled bi-center trial - Primary objective: to compare platelet number and function after processing and re-transfusion of the salvaged blood to the patient by using different cell saver devices. - Secondary (main) objectives: to compare a) the coagulation profile and b) the usage of blood products (frequency of administration of labile and stable blood products). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
| Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
| Completed |
NCT01696331 -
Text Messaging for Adherence in Adolescent Liver Transplant Recipients
|
N/A | |
| Recruiting |
NCT05051605 -
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
|
||
| Recruiting |
NCT05940857 -
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
|
||
| Completed |
NCT01598987 -
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
|
Phase 3 | |
| Active, not recruiting |
NCT05074160 -
OCS Liver Perfusion (OLP) Post-Approval Registry
|
||
| Completed |
NCT05087550 -
Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
|
||
| Recruiting |
NCT04836923 -
LIFT Intervention in Liver Transplant Candidates
|
N/A | |
| Not yet recruiting |
NCT03666689 -
Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
|
||
| Not yet recruiting |
NCT06088758 -
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
|
N/A | |
| Terminated |
NCT01230502 -
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
|
N/A | |
| Completed |
NCT00171509 -
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
|
Phase 4 | |
| Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06075745 -
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
|
Phase 2 | |
| Not yet recruiting |
NCT06280950 -
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
|
Phase 2 | |
| Completed |
NCT02057484 -
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
|
||
| Active, not recruiting |
NCT03577431 -
Liver Transplantation With Tregs at MGH
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06342557 -
Transitional ePRO Diary Liver
|
||
| Not yet recruiting |
NCT04265157 -
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
|